Literature DB >> 21187476

Alternative lengthening of telomeres as a prognostic factor in malignant fibrous histiocytomas of bone.

Toshihiro Matsuo1, Shoji Shimose, Tadahiko Kubo, Jun Fujimori, Yuji Yasunaga, Mitsuo Ochi.   

Abstract

BACKGROUND: Malignant fibrous histiocytoma (MFH) of bone is a rare primary malignant neoplasm. Recent studies indicate a positive correlation between the telomere maintenance mechanism and tumour aggressiveness in sarcomas. This study was undertaken to analyse the clinical significance of telomere factors in primary tumour samples from patients with MFHs of bone.
MATERIALS AND METHODS: Telomerase activity was measured in ten bone MFH specimens using a PCR-based TRAP assay. Telomere length was assessed using gel hybridisation. Quantitative detection of human telomerase reverse transcriptase (hTERT) was performed by real-time PCR.
RESULTS: Telomerase activity and hTERT expression were detectable in 100% of tumour samples and 50% of tumour samples had evidence of engagement of the alternative lengthening of telomere (ALT) mechanisms. ALT was a significant prognostic risk factor (p = 0.0316).
CONCLUSION: This study suggests that the presence of ALT telomere maintenance mechanisms indicates a poor prognosis for bone MFH patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21187476

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

Review 1.  Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.

Authors:  Jixuan Gao; Hilda A Pickett
Journal:  Nat Rev Cancer       Date:  2022-07-05       Impact factor: 69.800

2.  ALTernative Telomere Maintenance and Cancer.

Authors:  Robert L Dilley; Roger A Greenberg
Journal:  Trends Cancer       Date:  2015-10-01

3.  Correlation between p38 mitogen-activated protein kinase and human telomerase reverse transcriptase in sarcomas.

Authors:  Toshihiro Matsuo; Shoji Shimose; Tadahiko Kubo; Jun Fujimori; Yuji Yasunaga; Takashi Sugita; Mitsuo Ochi
Journal:  J Exp Clin Cancer Res       Date:  2012-01-16

4.  Telomerase-independent paths to immortality in predictable cancer subtypes.

Authors:  Stephen T Durant
Journal:  J Cancer       Date:  2012-01-31       Impact factor: 4.207

Review 5.  Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?

Authors:  Luca Pompili; Carlo Leonetti; Annamaria Biroccio; Erica Salvati
Journal:  J Exp Clin Cancer Res       Date:  2017-12-22

Review 6.  Telomere maintenance mechanisms in cancer: clinical implications.

Authors:  Roger R Reddel
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 7.  The Role of Alternative Lengthening of Telomeres Mechanism in Cancer: Translational and Therapeutic Implications.

Authors:  Marta Recagni; Joanna Bidzinska; Nadia Zaffaroni; Marco Folini
Journal:  Cancers (Basel)       Date:  2020-04-11       Impact factor: 6.639

Review 8.  ALT Positivity in Human Cancers: Prevalence and Clinical Insights.

Authors:  Danny MacKenzie; Andrea K Watters; Julie T To; Melody W Young; Jonathan Muratori; Marni H Wilkoff; Rita G Abraham; Maria M Plummer; Dong Zhang
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

9.  Prevalence and potentially prognostic value of C-circles associated with alternative lengthening of telomeres in canine appendicular osteosarcoma.

Authors:  Ludmila Bicanova; Theresa Kreilmeier-Berger; Martin Reifinger; Klaus Holzmann; Miriam Kleiter
Journal:  Vet Comp Oncol       Date:  2020-12-08       Impact factor: 2.613

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.